Polina Weitzenfeld

发表

Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways.

J. Ravetch, S. Bournazos, Polina Weitzenfeld, 2019, The Journal of clinical investigation.

Inflammatory mediators in breast cancer: Coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition

T. Meshel, A. Ben-Baruch, E. Shabtai, 2011, BMC Cancer.

Epidermal Growth Factor and Estrogen Act by Independent Pathways to Additively Promote the Release of the Angiogenic Chemokine CXCL8 by Breast Tumor Cells 1

T. Meshel, A. Ben-Baruch, Polina Weitzenfeld, 2011 .

Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity

J. Ravetch, Patrick T Smith, Polina Weitzenfeld, 2021, Proceedings of the National Academy of Sciences.

The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer.

A. Ben-Baruch, Polina Weitzenfeld, Adit Ben-Baruch, 2014, Cancer letters.

The Versatile World of Inflammatory Chemokines in Cancer

A. Ben-Baruch, Polina Weitzenfeld, Tal Leibovich-Rivkin, 2013 .

Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells

T. Meshel, A. Ben-Baruch, Polina Weitzenfeld, 2016, Oncotarget.

Chemokine axes in breast cancer: factors of the tumor microenvironment reshape the CCR7‐driven metastatic spread of luminal‐A breast tumors

S. Wiemann, D. Seliktar, T. Meshel, 2016, Journal of leukocyte biology.

Progression of Luminal Breast Tumors Is Promoted by Ménage à Trois between the Inflammatory Cytokine TNFα and the Hormonal and Growth-Supporting Arms of the Tumor Microenvironment

T. Meshel, A. Ben-Baruch, Nurit Meron, 2013, Mediators of inflammation.

Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cells.

T. Meshel, A. Ben-Baruch, Polina Weitzenfeld, 2011, Neoplasia.

Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways.

J. Ravetch, S. Bournazos, Polina Weitzenfeld, 2019, The Journal of clinical investigation.